WO2007023841A1 - Préparation d'agent pour la croissance des cheveux - Google Patents

Préparation d'agent pour la croissance des cheveux Download PDF

Info

Publication number
WO2007023841A1
WO2007023841A1 PCT/JP2006/316471 JP2006316471W WO2007023841A1 WO 2007023841 A1 WO2007023841 A1 WO 2007023841A1 JP 2006316471 W JP2006316471 W JP 2006316471W WO 2007023841 A1 WO2007023841 A1 WO 2007023841A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair growth
minoxidil
preparation
receptor agonist
present
Prior art date
Application number
PCT/JP2006/316471
Other languages
English (en)
Japanese (ja)
Inventor
Akiko Nakao
Natsuko Uematsu
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Priority to JP2007532144A priority Critical patent/JP5780690B2/ja
Publication of WO2007023841A1 publication Critical patent/WO2007023841A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a hair growth preparation comprising minoxidil as an active ingredient.
  • Minoxidil has a chemical name of 6- (1-piberidyl) -2,4-pyrimidinediamin-3-oxide, and has been reported for use as a hair restorer (see Patent Document 1), etc. There are many reports on hair growth, hair growth, and nourishing.
  • Non-patent Document 1 an increase in the hair density (hair diameter) of beaked monkeys was observed by application of latanoprost.
  • Patent Document 1 US Pat. No. 4,139,619
  • Patent Document 2 JP 2001-2535
  • Non-Patent Document 1 Acta Dermatol Venereol 82, 7-12 (2002)
  • An object of the present invention is to further improve the excellent hair growth effect of minoxidil.
  • the present invention provides
  • a hair growth composition comprising minoxidil and an FP receptor agonist.
  • the hair growth composition of the present invention has an excellent hair growth effect as compared to the case of the formulation component alone.
  • the amount of minoxidil compounded in the present invention is 1 to 5 W / V% (hereinafter referred to as “W / V%”) of the whole preparation (in the case of an aerosol) in terms of hair growth effect. (It may be indicated by “%”). This is because if the amount is too small, the hair growth effect is insufficient, and if the amount is too large, preparation of the preparation becomes difficult because, for example, crystals of minoxidil precipitate.
  • the blending amount of the FP receptor agonist blended in the present invention is preferably 0.00005 to 5% of the entire preparation from the viewpoint of hair growth promoting effect.
  • the FP receptor agonist compounded in the present invention is preferably PGF2a, PGF2a alkyl ester or latanoprost.
  • the alkyl ester is an alkyl ester having 1 to 6 carbon atoms, preferably a methyl ester.
  • ethanol As the solvent for the hair growth composition of the present invention, ethanol, water or a mixture thereof is preferred.
  • the blending amount in this case is preferably in the range of about 40 to 80% for ethanol and in the range of about 5 to 30% for water.
  • blending with ethanol is preferable because it provides a good feeling of use due to ethanol volatilization immediately after application.
  • the hair growth composition of the present invention preferably has a pH of 5.5 to 9.5 in terms of stability of the main ingredient, minoxidil, a feeling of use, a feeling of irritation to the skin during use, and a drug permeability.
  • the range of 5.5 to 6.5 is more preferable.
  • the pH can be adjusted by using commonly used acids and bases. Preferred examples include citrate, hydrochloric acid, lactic acid, phosphoric acid and salts thereof.
  • Medicinal effect preferably added to and added to the hair growth composition of the present invention
  • the components include menthol, vitamin E acetate, pantotulle ether, hinokitiol, glycyrrhetinic acid, diphenhydramine hydrochloride and the like.
  • various active ingredients and auxiliary ingredients used in general external preparations such as excipients, vasodilators (carp chloride- Hum, benzyl nicotinate, assembly extract, ginseng extract, red pepper tincture, etc.), antihistamines (such as istipendil hydrochloride), anti-inflammatory agents (such as guaiazulene), keratolytic agents (such as urea and salicylic acid), fungicides (such as Chlorhexidine darconate, isopropyl methylphenol, quaternary ammonium salt, pyrotatone olamine, etc., moisturizer (sodium hyaluronate, chondroitin sulfate, etc.), various animals and plants (yichi, buttonpi, licorice, bonito, Dumplings, bean paste, power wormwood, comfrey, ashtap
  • the hair growth composition of the present invention contains essential ingredients and, if necessary, other ingredients, and in the usual manner, lotions, aerosols, tonics, creams, ointments, gels It can be used as a suitable external preparation such as.
  • the back body hair of C3H mice male, 7 weeks old was shaved.
  • the hair growth state was scored with the scores shown in Table 1 on a daily basis from the administration start date of the test solution, and statistical analysis was performed using the scores on each observation day as an index.
  • Table 2 shows the scores on the 19th and 22nd days after the start of administration.
  • the present invention can be used as a pharmaceutical, a quasi-drug, a cosmetic, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bien qu’une préparation de minoxidil présente un excellent effet sur la croissance des cheveux, une préparation à effet encore meilleur est recherchée. Dans ce cadre, l'étude des divers moyens d'améliorer l'excellent effet sur la croissance des cheveux du minoxidil a mené à l'élaboration d'un agent de croissance des cheveux contenant un mélange de minoxidil et d'un agoniste de récepteur FP (PGF2α, ester alkylique de PGF2α ou latanoprost) qui présente un excellent effet sur la croissance des cheveux, non prévisible en ne considérant que les effets séparés de ses composants respectifs. Ainsi, la préparation selon l'invention peut être efficacement employée au titre de préparation à usage externe, telle qu'un produit pharmaceutique ou cosmétique.
PCT/JP2006/316471 2005-08-25 2006-08-23 Préparation d'agent pour la croissance des cheveux WO2007023841A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007532144A JP5780690B2 (ja) 2005-08-25 2006-08-23 発毛剤組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005243557 2005-08-25
JP2005-243557 2005-08-25

Publications (1)

Publication Number Publication Date
WO2007023841A1 true WO2007023841A1 (fr) 2007-03-01

Family

ID=37771583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/316471 WO2007023841A1 (fr) 2005-08-25 2006-08-23 Préparation d'agent pour la croissance des cheveux

Country Status (2)

Country Link
JP (1) JP5780690B2 (fr)
WO (1) WO2007023841A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013180229A1 (fr) * 2012-05-30 2013-12-05 旭硝子株式会社 Composition pour la croissance capillaire
US8686035B2 (en) 2003-08-12 2014-04-01 R-Tech Ueno, Ltd. Composition and method for promoting hair growth
US11918579B2 (en) 2019-08-07 2024-03-05 Aneira Pharma, Inc. Methods and compositions for the treatment of hair loss

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033497A1 (fr) * 1997-02-04 1998-08-06 Johnstone Murray A Procede permettant de stimuler le developpement du systeme pileux et la pousse des cheveux
WO2001074315A2 (fr) * 2000-03-31 2001-10-11 The Procter & Gamble Company Compositions et methodes de traitement de la perte de cheveux au moyen de prostaglandines non naturelles
WO2003009820A2 (fr) * 2001-07-25 2003-02-06 Alcon, Inc. Analogues de prostaglandine destines a favoriser la croissance des cheveux
JP2003155218A (ja) * 2001-09-10 2003-05-27 Lion Corp 養育毛組成物
WO2003092617A2 (fr) * 2002-05-03 2003-11-13 Combinatorx, Incorporated Combinaisons destinees au traitement de troubles cutanes inflammatoires

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
EP1358868A3 (fr) * 2002-04-23 2003-11-19 L'oreal Composition cosmétique pour favoriser la pousse et/ou empecher ou retarder la chute des cheveux

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033497A1 (fr) * 1997-02-04 1998-08-06 Johnstone Murray A Procede permettant de stimuler le developpement du systeme pileux et la pousse des cheveux
WO2001074315A2 (fr) * 2000-03-31 2001-10-11 The Procter & Gamble Company Compositions et methodes de traitement de la perte de cheveux au moyen de prostaglandines non naturelles
WO2003009820A2 (fr) * 2001-07-25 2003-02-06 Alcon, Inc. Analogues de prostaglandine destines a favoriser la croissance des cheveux
JP2003155218A (ja) * 2001-09-10 2003-05-27 Lion Corp 養育毛組成物
WO2003092617A2 (fr) * 2002-05-03 2003-11-13 Combinatorx, Incorporated Combinaisons destinees au traitement de troubles cutanes inflammatoires

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8686035B2 (en) 2003-08-12 2014-04-01 R-Tech Ueno, Ltd. Composition and method for promoting hair growth
WO2013180229A1 (fr) * 2012-05-30 2013-12-05 旭硝子株式会社 Composition pour la croissance capillaire
EP2857002A4 (fr) * 2012-05-30 2015-12-09 Asahi Glass Co Ltd Composition pour la croissance capillaire
JPWO2013180229A1 (ja) * 2012-05-30 2016-01-21 参天製薬株式会社 育毛用組成物
US11918579B2 (en) 2019-08-07 2024-03-05 Aneira Pharma, Inc. Methods and compositions for the treatment of hair loss

Also Published As

Publication number Publication date
JP5780690B2 (ja) 2015-09-16
JPWO2007023841A1 (ja) 2009-02-26

Similar Documents

Publication Publication Date Title
JP2005314323A (ja) 育毛剤組成物
JP5699476B2 (ja) 発毛剤
JP4940527B2 (ja) 持続性育毛組成物
JP4554805B2 (ja) 養毛料
JPH10265343A (ja) 持効性育毛剤
JP2005505528A (ja) オルニチンデカルボキシラーゼインヒビターの毛包輸送のための局所用組成物
WO2007023841A1 (fr) Préparation d'agent pour la croissance des cheveux
JP2002326913A (ja) 育毛組成物
JP2023099672A (ja) 外用医薬組成物
JP4604489B2 (ja) 持続性育毛製剤
JP7059671B2 (ja) 発毛剤
JPH10279437A (ja) 頭髪用化粧料
US10543227B2 (en) Hair growth composition
JPH0640858A (ja) 養毛料
JP6821916B2 (ja) 外用組成物
JP4892786B2 (ja) 持続性育毛製剤
JP2003012468A (ja) 養毛・発毛促進剤
JP2021123586A (ja) 外用医薬組成物
JP2021123587A (ja) 外用医薬組成物
US20150073005A1 (en) Composition for hair growth
JP2814090B2 (ja) 養毛料
JP3088835B2 (ja) 育毛剤
JP2021167298A (ja) 外用医薬組成物
JP2021123584A (ja) 外用医薬製剤
JP2001122739A (ja) 養毛料

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007532144

Country of ref document: JP

122 Ep: pct application non-entry in european phase

Ref document number: 06782924

Country of ref document: EP

Kind code of ref document: A1